A Phase I Study of TNP-470 in the Treatment of AIDS-Associated Kaposi's Sarcoma
Status:
Completed
Trial end date:
1997-02-01
Target enrollment:
Participant gender:
Summary
To assess toxicity and determine the MTD of intravenous TNP-470 administered weekly in
patients with AIDS-related Kaposi's sarcoma. To assess pharmacokinetics and tumor response of
the drug.
Since evidence shows that neovascularization is important in the development of Kaposi's
sarcoma, drugs that inhibit angiogenesis, such as TNP-470, may be of benefit in patients with
the disease.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)